Comments
Biogen's hemophilia drug meets late-stage trial goal
27.09.2012. | (Reuters) - Biogen Idec Inc said on Wednesday its experimental treatment for patients with hemophilia B, a rare inherited blood disorder that impairs coagulation, met the main goal of controlling bleeding in a late-stage trial....
